BPA Blood Levels
Bisphenol A (BPA) is an organic compound. It is a colorless solid that is soluble in organic solvents, but poorly soluble in water. Having two phenol functional groups, it is used to make polycarbonate polymers and epoxy resins, along with other materials used to make plastics. It is a controversial component of plastic bottles and canned food linings that have helped make the world's food supply safer. It has the potential to mimic the sex hormone estrogen if blood and tissue levels are high enough. Now, an analysis of almost 150 BPA exposure studies shows that in the general population, people's exposure may be many times too low for BPA to effectively mimic estrogen in the human body. The analysis, presented at the American Association for the Advancement of Science's annual meeting by toxicologist Justin Teeguarden of the Department of Energy's Pacific Northwest National Laboratory, Richland, Wash., shows that BPA in the blood of the general population is many times lower than blood levels that consistently cause toxicity in animals. The result suggests that animal studies might not reflect the human BPA experience appropriately.
Based on research by chemists at Bayer and General Electric, BPA has been used since the 1950s to harden polycarbonate plastics and make epoxy resin, and in the lining of food and beverage containers.
The first evidence of the estrogenicity of bisphenol A came from experiments on rats conducted in the 1930s, but it was not until 1997 that adverse effects of low-dose exposure on laboratory animals were first proposed. Modern studies began finding possible connections to health issues caused by exposure to BPA during pregnancy and during development.
"Looking at all the studies together reveals a remarkably consistent picture of human exposure to BPA with implications for how the risk of human exposure is interpreted," said Teeguarden. "At these exposure levels, exposure to BPA can't be compared to giving a baby the massive dose of estrogens found in a birth control pill, a comparison made by others."
In addition to evaluating the likelihood of BPA mimicking estrogen in humans, Teeguarden also analyzed another set of BPA studies that looked at the chemical's toxicity in animals and cells in the lab. These 130 studies are significant as a group because they refer to the exposures as low dose, implying they are very relevant to human exposures.
According to his analysis, however, the low doses actually span an immense range of concentrations, a billion-fold. In addition, only a small fraction of the exposures in these self-described low dose studies are in the range of human exposures, from 0.8 percent to 7 percent depending on the study.
"The term low-dose cannot be understood to mean either relevant to human exposures or in the range of human exposures. However, this is in fact what it has come to mean to the public, as well as many in the media," said Teeguarden.
The first analysis covered 30,000 individuals, including women and infants, in 19 countries. Human blood concentrations were calculated multiple ways using many kinds of exposure data.
Teeguarden looked to see if BPA concentrations were sufficiently high to be a significant source of estrogen-like activity in the blood. Researchers have long known that BPA can bind to the same proteins that estrogen does — called estrogen receptors — when estrogen is doing its job in the body. However, in most cases, BPA does so much more weakly than estrogen. To trigger biological effects through receptors, BPA concentrations have to be high enough in the blood to overcome that weakness.
"Systematically testing the estrogenicity, or the bioactivity of BPA at the part per trillion concentrations we expect in human blood would seem the most scientific way to substantiate or refute this conclusion," said Teeguarden.
Teeguarden analyzed the data in these studies using multiple independent approaches applied systematically to the data from thousands of individuals. The results showed that human blood levels of BPA are expected to be too far below levels required for significant binding to four of the five key estrogen receptors to cause biological effects.
In this analysis, Teeguarden compiled all the BPA studies that included the term low dose as it referred to human exposure by using such terms as low-concentration, environmentally relevant, or human exposure. From the 130 studies found, he and PNNL biologist Sesha Hanson-Drury compiled all the doses that were actually used in the studies.
The results showed that a small fraction of the low doses used in these studies are within the range of human exposures, with the vast majority being at least 10 to thousands of times higher than what humans are exposed to daily. In addition, the range of concentrations spans from upwards of 10 grams per kilogram of weight per day down to 100 picograms per kilogram of weight per day (a picogram is one millionth of a gram).
"Unfortunately, the low dose moniker has been used by some to promote the importance of selected toxicity studies, for example, in arguments to ban BPA," said Teeguarden. "For BPA and all chemicals, we need more accurate language to present these findings so the public and scientists in other disciplines can understand how human exposures compare to exposures in laboratory studies reporting toxicity."
Overall, empirical evidence supporting the negative health effects of BPA varies significantly across studies. Opinions vary greatly about the health effects of BPA. Some studies conclude that BPA poses no health risks while others state that BPA causes a number of adverse health effects. In general, the European Commission's Scientific Committee on Food, the EU's European Chemicals Bureau, the European Food Safety Authority, and the US Food and Drug Administration have concluded that current levels of BPA present no risk to the general population.
For further information see BPA Studies.
Bottles image via Wikipedia.